Comparison
Ecnoglutide vs. Exenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
141758-74-9
Molecular weight
no data
4186.6 g/mol
Half-life
144 h
2.4 h
Sequence
no data
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSMechanism of action
Ecnoglutide
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
5
4
Effects recorded
4
3
Open conflicts
0
1
Documented adverse events
1
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Ecnoglutide and Exenatide?
- Ecnoglutide is classified as "Metabolic", while Exenatide is classified as "Metabolic". Ecnoglutide: Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes. Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ecnoglutide or Exenatide?
- The highest available evidence level is "Human RCT" for Ecnoglutide and "Human RCT" for Exenatide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ecnoglutide and Exenatide in Germany and the United States?
- Germany: Ecnoglutide — Unapproved, Exenatide — Prescription. United States: Ecnoglutide — Unapproved, Exenatide — Prescription. These are factual summaries with source and review date on the individual pages.